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Newly developed drugs often have poor bioavailability due to their poor water solubility 
(BCS class 2 drugs). It is therefore necessary to develop new strategies to enhance their 
solubility and their activity, among which, Self-Emulsifying Drug Delivery System (SEDDS). 
The efficacy of the drugs contained in these preparations is mainly affected by the solid state 
and the particle size of the active pharmaceutical ingredient (API).  
However, it is quite complex, long and expensive to characterize these parameters with 
classical techniques such as X-Ray powder diffraction, differential scanning calorimetry or 
hot stage microscopy. 
The present article presents, through a case study, the advantages of the Raman hyperspectral 
imaging in the characterization of such formulations. Indeed, Raman chemical imaging may 
fully characterize SEDDS with single equipment and operator in a non-destructive way 
allowing the follow-up of the formulation during stability studies. Raman imaging is therefore 
a tool of choice in the PAT framework since it increases the knowledge of the formulation 
and the process. 
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A quantitative multivariate method using Raman hyperspectral imaging to assay the API in 
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1. Introduction 
Following the Biopharmaceutical Classification System (BCS), drugs may be characterized 
according to their membrane permeability and their aqueous solubility (Amidon et al., 1995). 
Even if the actual tendency is to produce biopharmaceutical active pharmaceutical ingredient 
(API), the huge majority of new chemical entities (NCE) are little molecules obtained by 
organic chemistry synthesis. This implies that most NCE show a poor water solubility (Li et 
al., 2009) and are classified as BCS class 2 (poor solubility and high permeability). However, 
the main problem with BCS class 2 drugs is that they exhibit relatively poor bioavailability.  
Several strategies may be used to address this: particle size decrease, polymorphism, 
amorphous drugs, complexation (with cyclodextrins or surfactants), solid solutions and 
dispersion, soluble prodrugs and salts (Leuner and Dressman, 2000). Another approach is the 
use of Self-Emulsifying Drug Delivery System (SEDDS). These liquid or semi-solid 
formulations are encapsulated into hard or soft capsules and generate an emulsion in the 
gastrointestinal tract facilitating the absorption of the drug (Mullertz et al., 2010). There exist 
a large variety of excipients that can be used ranging from non-polar lipids to polar lipids. 
Pouton et al. (Pouton, 2006) proposed a Lipid Formulation Classification System (LFCS) 
categorizing the lipid based formulations according to their composition. The LFCS classifies 
the lipid based formulations as Type I if it is composed exclusively of oils, Type II if it is a 
mix of oils and water-insoluble surfactants, Type IIIA are the formulations composed of 
mainly of oils and small proportion of water-soluble surfactant, Type IIIB are composed of a 
small proportion of oils and a majority of water-soluble surfactants and hydrophilic co-
solvents and finally Type IV are composed of a mix of surfactants and co-solvents. The 
studied formulation is categorized as type IV formulation. This type of formulation allows an 
increased API charge compared to Type I formulations and produces very fine dispersions in 
an aqueous medium (Mullertz et al., 2010). 
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The main parameters that influence the activity of such formulations are the solid-state and 
the particle size of the API. The solid-state is commonly characterized using differential 
scanning calorimetry (DSC) (Balakrishnan et al., 2009; Craig, 2006; Kang et al., 2012) or X-
Ray powder diffraction (XRPD) (Docoslis et al., 2007; Hu et al., 2012; Wei et al., 2012) or 
vibrational spectroscopy (Milović et al., 2012; Nazzal et al., 2002; Stillhart and Kuentz, 
2012). However these techniques are costly and require a highly trained user (for XRPD) and 
are destructive (for DSC).  
 
Particle size analysis of lipid based formulations is a hard task since particles are formed 
during the cooling of the melt API/excipients matrix. So, it must be performed on the semi-
solid dosage form after manufacturing. Therefore some researchers rather analyze the particle 
size of the produced emulsion in an aqueous medium (Agarwal et al., 2009; Ali et al., 2008). 
However, this is not applicable as quality control of a commercial formulation. Microscopic 
analysis with scanning or transmission electronic microscopes (SEM or TEM) may also be 
used (Balakrishnan et al., 2009; Yi et al., 2008a, 2008b; Zhang et al., 2012). But once again it 
is costly, require highly trained users and it can only be used to see very small surfaces 
making representativity of the sampling a very big issue. Optical hot stage microscopy 
(possibly with polarized light) may also be used if the particle size is large enough (Bikiaris et 
al., 2005; Sprunk et al., 2012). But this technique has many drawbacks such as temperature 
degradation, polymorphism conversion but most of all the melt down of the smallest particles 
in the matrix making only possible the observation of the biggest particles.  
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Another technique that can be used to characterize both polymorphic state and particle size of 
the API is the Raman hyperspectral imaging. This technique combines the information 
obtained by Raman spectroscopy with spatial information.  
Three configurations of Raman hyperspectral imaging systems exist: point mapping, line 
scanning and global imaging. The point scanning mode is by far the most used configuration. 
It consists of recording a spectrum at a specific spatial location, then the sample moves, 
another spectrum is recorded at an adjacent location and so on until the whole mapping area is 
covered. The line scanning mode records the spectra of a complete line of the sampled area 
simultaneously which fastens the analysis. Finally, in the global imaging configuration, the 
whole sample is illuminated and the intensity of a fixed number of wavenumbers is recorded 
returning a complete image of the sample for each wavenumber. In this case, the spatial 
resolution is limited by the number of pixels of the detector (Sacré et al., 2014a). In the 
present study, each imaging system worked in the point mapping mode. 
Raman spectroscopy allows to characterize the solid-state of pharmaceutical powders 
(Brittain, 2009; Simone et al., 2014) but also to obtain quantitative information of an API 
(Breitkreitz et al., 2013) and because of the low wavelength laser used (visible to NIR light), 
it may provide high resolution (~1µm) images (Adar et al., 2006). 
It is therefore possible with a single technique to obtain both solid-state, quantitative and 
particle size information of a sample. Raman hyperspectral imaging is surely the technique of 
choice for the characterization of solid dispersions and among them SEDDS. 
In the present study, we developed and validated a quantitative method based on 
hyperspectral Raman imaging to quantify a BCS 2 API in a lipid based formulation. To the 
author’s best knowledge, it is the first time that a hyperspectral imaging quantitative method 
has been fully validated using the “total error” approach.  
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Moreover, two formulations were produced, one with the API totally dissolved in the matrix 
and a second one with 70% of the API dissolved in the matrix and 30% added as bulk 
powder. The second formulation mimics a bad processed medicine and Raman hyperspectral 




The studied formulation consists of a BCS 2 API dispersed in a lipid matrix at a concentration 
of 28% (w/w). The excipient part is composed of lauroyl macrogol-32 glycerides (>50%), 
hydroxypropyl cellulose, macrogol 20000, sodium starch glycolate and ascorbyl palmitate by 
order of importance.  
The API and excipients were kindly donated by Galephar M/F. 
2.1.1. Validation 
Calibration and validation samples were prepared at 50, 75, 100, 125 and 150% of the target 
API concentration. Only the ratio API/excipients was changed keeping the ratio between 
excipients constant. For each concentration level, three independent series were realized with 
three replicates per series.  
The samples were prepared by dispersing the melt API in the melt excipients. Once dispersed, 
the mix is cooled to room temperature and three small cylindrical samples (1 cm of diameter 
and 0.5 cm high) are deposited on a microscope slide constituting a series. Samples were then 
milled with a Leica EM Rapid milling system equipped with a tungsten carbide miller (Leica 
Microsystems GmbH, Wetzlar, Germany) to prepare their surface for Raman imaging 
experiments.  
After the Raman imaging experiments, samples were assayed by HPLC. 
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2.1.2. Industrial samples 
The validated quantitative method was applied on industrial samples. Three samples per batch 
and three different batches (517811J, 12F04, 11I19) were analyzed. The semi-solid samples 
were taken out of the hard capsules and a sagittal cut was performed before milling. 
Once mapped, samples were analyzed by HPLC. 
2.1.3. Samples for the case study 
Two preparations were compared and fully characterized using Raman imaging:  
 Preparation 1: 100% of the API has been dissolved in the melted excipients. This 
preparation corresponds to an industrial batch without manufacturing issue. 
 Preparation 2: 70% of the API has been dissolved in the melted excipients and the 
remaining 30% were added as crystalline bulk powder to the solidified cooled 
preparation. This preparation mimics an industrial batch that encountered issues 
during process. 
 
2.2. Reference method 
2.2.1. Chemicals 
Methanol HPLC grade was purchased from J.T. Baker (Deventer,Netherlands). Water was 
purified by a Millipore system (18.2 MΩ/cm resistivity, Milli-Q) before filtration through a 
0.22 µm Millipore Millipak
®– 40 disposable filter units (MilliporeCorporation, USA).  
2.2.2. Instrument and chromatographic conditions 
The HPLC experiments were performed on an Alliance 2690 HPLC system (Waters, Milford, 
USA) coupled to a 2996 PDA detector (Waters). Data acquisition and treatment were realized 
with the Empower 2.0 software (Waters). 
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The analysis was carried out with a LiChrospher® 100 RP-8 column (125 × 4 mm, 5 μm; 
Merck, Darmstad, Germany) kept at 35°C. Mobile phase consisted of a mixture of MeOH and 
water (80:20, v/v).  
The HPLC system was operated at isocratic mode during 8 min at a flow rate of 0.8 mL min
-1
 
and the injected volume was 30 µL. UV detection was performed at 288 nm. 
2.2.3. Sample preparation 
All dilutions were performed in a mixture of water and MeOH (1:1, v/v) except for the first 
step performed in 100% MeOH.  
Calibration standards were obtained by successive dilutions of a stock solution of 40 mg of 
API in 100.0 mL MeOH to reach the final concentrations of 40, 60, 80, 100 and 120 µg mL
-1
. 
Analysed samples were prepared by diluting 282 mg of semi-solid preparation (~80 mg of 
API at the 100% level) in 100.0 mL MeOH. This solution is sonicated for 15 minutes at 45°C, 
cooled to room temperature and then diluted to reach the final concentration of 80 µg mL
-1
 (at 
the 100% level). 
Samples concentrations are back-calculated using the linear regression model as response 
function. 
 
2.3. Dissolution studies 
Dissolution of the two case study preparations (see 2.1.3.) was performed with a paddle 
apparatus (European pharmacopoeia apparatus 2). Dissolution profiles were constructed with 
the mean dissolution values from six dissolution baths for each preparation. Test samples 
consisted of 675 mg of each preparation. Baths were heated at 37°C, dissolution medium 
consisted of pH 5.5 phosphate buffer with 3% m/v tween 80 and 0.32% m/v pepsine and the 
stirring speed was of 100 rpm. Five millilitres aliquots were collected from the 900 mL 
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dissolution bath after 30, 60, 90, 120, 150 and 180 minutes.  These aliquots were then 
analyzed by HPLC. 
 
2.4. Raman hyperspectral imaging analyses 
2.4.1. Quantitative analyses 
Raman hyperspectral images were collected with a dispersive Raman spectrometer 
RamanStation 400F (Perkin Elmer, MA, USA) equipped with a two-dimensional CCD 
detector (1024 × 256 pixel sensor). The laser excitation wavelength used was 785 nm with a 
power of 100 mW.  
The measured spectral region was 3050-90 cm
-1
 and the spectral resolution was equal to 2 cm
-
1
. One accumulation with a 1 second exposure time was performed per sample mapping point. 
The distance between 2 consecutives mapping measurements was fixed at 200 µm. 
Background acquisition during mapping was repeated each 20 minutes. The spectra were 
collected with the Spectrum 6.3.2.0151 (Perkin Elmer) software.  
 
The samples used for the calibration and validation of the quantitative model were mapped 
over an area of 6 x 6 mm² (squares of 30 x 30 pixels). 
Industrial samples were mapped over an area of 7.6 x 5 mm² (rectangles of 38 x 25 pixels). 
Case study samples were mapped over an area of 12 x 12 mm² (squares of 60 x 60 pixels).  
2.4.2. Microscopic analyses 
Microscopic imaging analyses of the case study preparations were performed with a Labram 
HR Evolution (Horiba scientific) equipped with a two-dimensional Newton 970 front-
illuminated EMCCD detector (1600 × 200 pixel sensor) (Andor Technology Ltd.), a Leica 
50x Fluotar LWD objective and a 785 nm laser with a power of 45mW (XTRA II single 
frequence diode laser, Toptica Photonics AG).  
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A 300 gr/mm grating fixed at 1200 cm
-1
 (464–1853 cm-1) was used to perform the mappings 
with a single acquisition of 0.1 sec (SWIFT ™ mode). The confocal slit-hole was fixed at 200 
µm. A binning factor of 2 and an electron multiplying gain of 150 were applied. The spectra 
were collected with the LabSpec 6 (Horiba Scientific) software. 
 
One medium resolution mapping of 2500x2500 μm² was performed per preparation with a 
pixel size of 10x10 μm² (spatial resolution of ~10μm, square mapping of 250 x 250 pixels).  
Three high resolution mappings of 100x100 μm² were performed per preparation with a pixel 
size of 0.5x0.5 μm² (resolution of ~1μm, square mapping of 200 x 200 pixels).  
 
2.5. Data processing 
Once acquired, the hyperspectral images were unfolded and the spectra were baseline 
corrected using the Asymmetric Least Squares (AsLS) (Eilers, 2003) algorithm with a λ value 
of 10
5
 and a p value of 10
-3
. After baseline correction, cosmic rays have been removed with 
the algorithm developed by Sabin et al. (Sabin et al., 2012) with a k value of 15. 
The region of interest selection performed with the mapping of the case study samples has 
been performed with the “htmaskingroipoly” function of the Hypertools toolbox (Amigo, 
2010; Vidal and Amigo, 2012). 
 
All computations were realized with Matlab R2013a (version 8.1, The Matworks, Natick, 
MA, USA).  
 
2.5.1. Quantitative model 
The average spectrum of each pre-processed calibration mapping was taken to build a PLS 
regression model. The partial least squares (PLS) analysis of the data has been performed 
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with the SIMPLS algorithm (de Jong, 1993) using the PLS Toolbox 7.8 (Eigenvector 
Research, Wenatchee, WA, USA). Several other approaches were envisaged (median 
spectrum, ten highest correlated to median spectrum …) but these approaches gave worse or 
comparable results and were then abandoned.  
The constituted calibration set was standard normal variate (SNV) and mean center corrected 
before building the model.  
A random sample selection cross-validation was performed (10 splits and 10 iterations) to 
select the number of latent variables to keep. The best model was obtained keeping 2 latent 
variables with a root mean squared error of cross-validation (RMSECV) of 2.57 %. 
 
The validation samples mappings were then analyzed with the PLS model and the mean 
predicted concentration of each map was used to validate the model. 
 
This method has been validated using the “total error” approach in accordance with the 
validation requirements in the ICH Q2 R1 norm (Hubert et al., 2008, 2007a, 2007b, 2004). 
The validation of the assay method has been performed between 50-150% of the target value. 
Validation protocol consisted of one operator, one instrument, three replicates per series and 
three series. Acceptance limits were set at +/- 10% and the β-expectation tolerance intervals 
were computed at a probability β of 95%. All validation calculations were performed with E-
noval
®
 version 3.0 (Arlenda S.A., Liege, Belgium). 
 
2.5.2. Particle size analysis 
 
Medium and high resolution mappings of case study samples were baseline corrected by 
AsLS (λ value of 105 and p value of 10-3). The baseline corrected mappings were then 
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analyzed by multivariate curve analysis – alternating least squares (MCR-ALS) (Jaumot et al., 
2005) with two components and with a non-negativity constraint on the spectra and 
concentration resolution. 
 
The resolved concentration map of the API is then binarized and the particles size estimated. 
The particle size analysis has been performed using Image J version 1.47v (Schneider et al., 
2012). 
 
3. Results and discussion 
3.1. Quantitative method validation 
The quantitative regression PLS model has been fully validated within the +/- 10% 
acceptance limits. The classical +/- 5% acceptance limits for the assay of pharmaceutical 
specialties were not achievable because of sampling issues. Indeed, only a small slice of the 
sample is mapped and the representativity of the sample is directly linked to the homogeneity 








Figure 1: Accuracy profile obtained from the PLS regression model. The solid line is the relative bias, 
the dashed lines are the 95% β-expectation tolerance limits and the dotted lines represent the 
acceptance limits (+/-10%). 
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Table 1 collects the values of trueness (relative bias), precision (repeatability and intermediate 
precision) and accuracy (relative β-expectation tolerance limits) obtained during the 
validation process. These information may be put together in a single image called accuracy 
profile (Figure 1) demonstrating that 95% of future results will fall within the +/- 10% 
acceptance limits. 
Table 1: Validation criteria of the developed PLS quantitative method. 
 
As one can see, the profile has a small bias but quite large precision values due to the 
sampling issue. The computed RMSEP value for the validation set was of 2.41%. The 
accuracy profile demonstrates that the computation of the sole RMSEP does not provide 
valuable information of the method accuracy (De Bleye et al., 2012). 
It is clear that hyperspectral Raman imaging quantitative performances are fairly inferior 
compared to a classical HPLC method for solid pharmaceutical preparations. But the main 
advantage of using a validated quantitative model is to obtain reliable quantitative information 
at the pixel level and therefore more reliable chemical images. Another advantage is the 
possibility to obtain reliable constitutional homogeneity information with the statistics of the 






















      50 0.03 2.42 2.87 [-7.69; 7.75] 6.23 
75 -1.13 1.88 1.88 [-5.74; 3.48] 3.97 
100 1.69 1.99 2.21 [-4.20; 7.58] 4.77 
125 1.40 2.41 1.72 [-5.68; 8.47] 5.85 
150 0.54 1.82 1.82 [-3.93; 5.00] 3.85 
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The developed model was applied on real life industrial samples. Results are shown in Table 
2. As one can see, the errors (differences between HPLC and PLS predicted values) are well 
comprised between the acceptance limits. Beside this quantitative analysis, Raman imaging 
allows also to obtain information regarding the distributional homogeneity of the API among 
the sample. 
Table 2: Results of the assay of industrial samples by both HPLC and the validated PLS 










Figure 2 shows the distribution map of the API in three industrial samples. Both have a 
correct API predicted content (98.5%, 100.0% and 104.2% for sample A, B and C 
respectively) but they exhibit different distribution pattern. In order to obtain an objective 
value regarding this difference of distribution, the Distributional Homogeneity Index (DHI) 
approach was used (Sacré et al., 2014b). The smaller and close to 1 the DHI value, the more 
homogeneous the sample. Sample A, B and C returned DHI values of 3.53, 8.87 and 4.51 
respectively (the number of simulations was set to 100). This result confirms that sample B is 
the less homogeneous followed by sample C and sample A. The process should therefore be 













     517811J 1 98,04 99,69 1,65 
 2 98,52 96,07 -2,45 
 3 97,05 93,97 -3,08 
     12F04 1 99,23 95,61 -3,62 
 2 100,03 95,41 -4,62 
 3 99,13 96,28 -2,85 
     11I19 1 98,04 101,80 3,76 
 2 98,52 104,17 5,65 
 3 97,05 99,99 2,94 
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conditions during formulation development. The DHI values may also be used in a design of 
experiment as response. 
 
a.     b.    c. 
       
Figure 2: 
a. Distribution map of the API obtained applying the developed PLS regression model on an 
industrial sample (sample A). 
b. Distribution map of the API obtained applying the developed PLS regression model on an 
industrial sample (sample B). 
c. Distribution map of the API obtained applying the developed PLS regression model on an 
industrial sample (sample C). 
 
3.2. Case Study 
After developing and validating the quantitative model, hyperspectral imaging was used to 
fully characterize a SEDDS formulation. To illustrate this case study, two preparations were 
realized: one with the API fully dissolved in the lipidic matrix (preparation 1) and another 
with 70% of the API dissolved and 30% added after cooling of the matrix mimicking a 
problem in the manufacturing process (preparation 2).  
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Figure 3 shows the dissolution profiles of both preparations. A difference may be seen since 
the two curves are parallel. The curve of preparation 2 reaching a maximum of 88.3% of API 
dissolved after 180 minutes while preparation 1 reaches 99.4% at the same time.  
 
 
Figure 3: Dissolution profiles obtained for the two case study preparations. Each point is the mean 
value of six dissolution baths.  
 
Based on these results, three critical parameters such as solid-state, concentration and particle 
size of the API should be checked. Indeed, it is often expected to be amorphous in order to 
enhance the API dissolution rate. Figure 4a shows the spectra of the three polymorphic forms 
of the API while Figure 4b shows the spectra extracted from the mapping experiments. As can 
be seen, the API in both preparations is under its polymorphic 1 (stable) form denoting its 
crystalline character. It can therefore be concluded that the API is not molecularly dispersed 
(solid solution) but is present as small crystalline particles dispersed in the excipient matrix. 
The mean assay values of preparation 1 and 2 are 101.3% and 101.0% respectively. The 




a.       b. 
 
Figure 4: 
a. Reference spectra of the different API polymorphic forms. 
b. Extracted API spectra from the mapping analysis of preparations 1 and 2. 
 
However, when looking at the constitutional homogeneity, the relative standard deviation 
among pixels is of 3.3% and 11.9% for preparation 1 and 2 respectively. This difference is 
clearly seen when looking at the Figure 5a and b. Preparation 1 has a much more homogenous 
distribution of pixel concentrations while preparation 2 has very concentrated areas and areas 
with depletion in API. 
a.       b. 
        
Figure 5: PLS scores for preparation 1 (a) and 2 (b) obtained with macroscopic mapping of the 
dosage forms. 
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These results indicate that the major difference between both preparations is situated at the 
particle size level. Therefore, higher resolution mappings were realized with a confocal 
microscope to investigate particle sizes up to 1 µm.  
Figures 6 and 7 show the results of the mappings at a medium resolution (pixel size of 10 µm) 
and high resolution (pixel size of 0.5 µm), respectively. Particles of each mapping have been 
analyzed and their modal, minimal and maximal diameters of theoretically spherical particles 
computed. Results are shown in Table 3. Particles of diameter <15 µm and 1.5 µm were 
discarded from the analysis of the medium and high resolution mappings respectively to only 
take into account reliable size computations. It may be noticed from Figure 6 that a part of the 
API is also finely distributed at a sub-micron level.  
 
a.      b. 
 
Figure 6: Medium resolution maps of the API obtained by MCR-ALS for the preparation 1 (a) and 2 







a.     b.    c. 
       
d.     e.    f. 
         
Figure 7: High resolution maps of the API obtained by MCR-ALS for the preparation 1 (a, b, c) and 2 
(d, e, f). The pixel size is 0.5 µm. 
 
Both preparations have approximately the same modal and minimal particle diameter. 
However, a difference is highlighted in Table 3 regarding the maximal diameter and 
particularly at the number of particles. Indeed, preparation 1 has a much higher proportion of 
small particles (567 particles detected in the high resolution mapping versus 19 particles in 
the medium resolution mapping) than preparation 2 (326 particles detected in the high 
resolution mapping versus 300 particles in the medium resolution mapping). This confirms 
that the particle size difference between the two preparations is responsible of the difference 




Table 3: Number of particles, modal, minimal and maximal diameter of theoretically spherical 
particles. 
 
It appears from these results that the control of particle size in the final dosage form could be 
a good quality control test since it is directly related to the bioavailability of the API and 




The present article shows for the first time the validation of a quantitative Raman imaging 
method following the “total error” concept. Due to the sampling representativeness issue, 
limits of acceptation were set at +/- 10%. The validated quantitative method allowed 
obtaining reliable quantitative data per pixel and therefore more representative chemical 
images of the sample. 
 
A case study with the analysis of two preparations (one with the API fully dissolved and 
another with the API partially dissolved in the lipidic matrix) showed how Raman chemical 
imaging analysis may help to characterize lipid based formulations of poorly soluble APIs 














1 19 17.6 17.2 22.8 
2 300 17.8 17.2 188.8 
100x100 
µm² 
1 567 1.7 1.6 14.0 
2 326 1.8 1.6 41.8 
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Beside these techniques, Raman hyperspectral imaging may be successfully used to fully 
characterize lipid based formulations. Indeed, with a single equipment, one may obtain 
quantitative information, know the solid-state form and the particle size distribution of the 
API in a non-destructive way. This characteristic of Raman spectroscopy is particularly useful 
for stability studies that can be performed on the same samples all along. 
 
It can therefore be concluded that Raman hyperspectral imaging is the technique of choice for 
the full characterization of lipid based formulations. 
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